Key facts
- Depixus’s last known valuation is $74.5M (Dec 2021).
- It has raised $42.1M.
- Notable investors include Innovate UK, Bpifrance, Agoranov, Casdin Capital, Lansdowne Partners — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Depixus
- ·The full record, as it builds
Funding rounds
No funding rounds for Depixus are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Depixus
Developer of a magnetic force spectroscopy platform designed to analyze thousands of individual biomolecular interactions in real time. The company provides a system to observe protein-protein interactions, RNA binding, enzyme activity, and other molecular interactions, enabling researchers to study molecular heterogeneity, molecular dynamics, and rare events.
- Sector
- Healthcare
- HQ
- Courbevoie, France
- Founded
- 2012
- Employees
- 57
- Website
- depixus.com/
- Ownership
- Privately Held (backing)
Depixus doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Depixus shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Depixus in its N-PORT filings yet. We sweep new filings monthly.